Left ventricular conduits to coronary arteries and methods for coronary bypass

• US 6,945,949 B2
• Filed: 07/01/2002
• Issued: 09/20/2005
• Est. Priority Date: 01/30/1998
• Status: Expired due to Fees

• Current Assignee: Horizon Technology Funding Co. LLC (Horizon Technology Finance Management LLC)
• Original Assignee: Percardia, Inc.
• Inventors: Wilk, Peter J.
• Primary Examiner(s): Bianco, Patricia
• Application Number:
  US10/184,933
• Publication Number:
  US 20020165479A1
• Time in Patent Office: 1,177 Days
• Field of Search: 604 8- 10, 604 27- 30, 604/500, 604506- 9, 604/511, 604/264, 604/523, 604530- 2, 604/537, 604285- 88, 128/898, 623/1.1, 623 111- 112, 623/1.15, 623/1.17, 623/1.18, 623/1.2, 623 121- 125, 623 13- 132, 623 136- 139, 623 14- 148, 623/1.49, 623/11.11, 623/23.64, 623 2367- 2368, 623 237- 2371, 623 2375- 2376, 623920- 21, 623915- 16, 606/108, 606/151, 606153- 54, 606/159, 606/167, 606/170, 606184- 85, 606191- 92, 606194- 95, 606198-200, 424/400, 424422- 26, 427/2.1, 427/2.14, 427 221- 225, 427 228- 229
• US Class Current: 604/8
• CPC Class Codes: A61B 17/0057 Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect sutures A61B17/04; closing rectum or urethra near body surface A61F2/0009
• CPC Class Codes: A61B 17/11 for performing anastomosis; Buttons for anastomosis
• CPC Class Codes: A61B 17/3468 for implanting or removing devices, e.g. prostheses, implants, seeds, wires devices for implanting seeds A61M37/0069
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/00252 for by-pass connections, i.e. connections from heart chamber to blood vessel or from blood vessel to blood vessel
• CPC Class Codes: A61B 2017/00637 for sealing trocar wounds through abdominal wall
• CPC Class Codes: A61B 2017/00654 entirely comprised between the two sides of the opening
• CPC Class Codes: A61B 2017/1107 for blood vessels
• CPC Class Codes: A61B 2017/1135 End-to-side connections, e.g. T- or Y-connections Y-shaped blood vessel prostheses A61F2002/065
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/0215 by means inserted into the body catheters A61M25/00
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/6862 Stents
• CPC Class Codes: A61B 5/6876 Blood vessel
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61F 2/064 with special features to facilitate anastomotic coupling anastomosis of natural blood vessels A61B17/11
• CPC Class Codes: A61F 2/2493 Transmyocardial revascularisation [TMR] devices
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2/94 Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
• CPC Class Codes: A61F 2002/8486 : provided on at least one of the ends
• CPC Class Codes: A61F 2002/91508 : the meander having a difference in amplitude along the band
• CPC Class Codes: A61F 2002/91516 : the meander having a change in frequency along the band
• CPC Class Codes: A61F 2002/91525 : within the whole structure different bands showing different meander characteristics, e.g. frequency or amplitude
• CPC Class Codes: A61F 2002/91533 : characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2002/91575 : connected peak to trough
• CPC Class Codes: A61F 2220/0008 : Fixation appliances for connecting prostheses to the body
• CPC Class Codes: A61F 2220/0016 : with sharp anchoring protrusions, e.g. barbs, pins, spikes
• CPC Class Codes: A61F 2250/0002 : for data transfer
• CPC Class Codes: A61F 2250/0039 : differing in diameter
• CPC Class Codes: A61F 2250/0067 : Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61M 27/002 : Implant devices for drainage of body fluids from one part of the body to another intraocular A61F9/00781; middle ear A61F11/202

Abstract

A method of treating a heart may include providing an implant having a first end and a second end, placing the implant in a heart wall between a heart chamber and a blood vessel such that the first end of the implant is in flow communication with at least one of the geart chamber and the blood vessel, and delivering an angiogenesis factor in a time-relaease mannor to the heart wall proximate the implant.

Claims

1. A method of treating a heart, the method comprising:

providing an implant having a first end and a second end;

placing the implant in a heart wall between a heart chamber and a blood vessel such that the first end of the implant is in flow communication with at least one of the heart chamber and the blood vessel;

delivering n angiogenesis factor in a time-release manner to the heart wall proximate the implant; and

controlling the rate of the delivery of the angiogenesis factor,

wherein the implant is porous and controlling the rate of the delivery includes controlling a porosity of the implant.

2. The method of claim 1, wherein delivering the angiogenesis factor includes delivering the angiogenesis factor via the implant.

3. The method of claim 2, wherein the implant is configured to carry the angiogenesis factor.

4. The method of claim 1, wherein the implant includes a stent.

5. The method of claim 1, wherein the implant includes a plug.

6. The method of claim 1, wherein placing the implant includes placing the first end of the implant in flow communication with the heart chamber and placing the second end of the implant in flow communication with the blood vessel.

7. The method of claim 1, wherein delivering the angiogenesis factor in the time-release manner includes permitting the implant to degrade over time.

8. The method of claim 1, wherein delivering the angiogenesis factor in the time-release manner includes permitting the implant to be absorbed by the heart wall over time.

9. The method of claim 1, wherein delivering the angiogenesis factor in the time-release manner includes permitting the implant to dissolve over time.

10. The method of claim 1, further comprising delivering at least one additional agent to the heart wall proximate the implant.

11. The method of claim 10, wherein delivering the angiogenesis factor and the at least one additional agent includes delivering the angiogenesis factor and the at least one additional agent via an implant having the angiogenesis factor and the at least one additional agent applied thereto.

12. The method of claim 11, further comprising controlling the rate of delivery of each of the angiogenesis factor and the at least one additional agent.

13. The method of claim 1, wherein placing the implant includes placing the first end of the implant in flow communication with a left ventricle.

14. The method of claim 1, wherein placing the implant includes placing the first end of the implant in flow communication with a coronary artery.

15. The method of claim 1, wherein placing the implant includes placing the second end of the implant within the heart wall.

16. A method of treating a heart, the method comprising:

providing an implant having a first end and a second end;

placing th implant in a heart wall between a heart chamber and a blood vessel such that the first end of the implant is in flow communication with at least one of the heart chamber and the blood vessel;

delivering an agent in a time-release manner to the heart wall proximate the implant; and

controlling the rate of the delivery of the agent,

wherein th implant is coated with a layer including the agents,

wherein th implant is porous and controlling the rate of the delivery includes controlling a porosity of the implant.

17. The method of claim 16, further comprising delivering at least one additional agent to the heart wall proximate the implant.

18. The method of claim 17, wherein delivering the agents includes delivering the agents via an implant having multiple agents applied thereto.

19. The method of claim 18, further comprising controlling the rate of delivery of each of the agents.

20. The method of claim 16, wherein the implant includes a stent.

21. The method of claim 16, wherein the implant includes a plug.

22. The method of claim 16, wherein the agent is chosen from angiogenesis factors, nucleic acid instructions for angiogenesis factors, growth factors, genes, drugs, and pharmaceutical compounds.

23. The method of claim 16, wherein the layer is made of a polymeric material.

24. The method of claim 16, wherein placing the implant includes placing he first end of the implant in flow communication with the heart chamber and placing the second end of the implant in flow communication with the blood vessel.

25. The method of claim 16, wherein delivering the agent in the time-release manner includes permitting the implant to degrade over time.

26. The method of claim 16, wherein delivering the agent in the time-release manner includes permitting the implant to be absorbed by the heart wall over time.

27. The method of claim 16, wherein delivering the agent in the time-release manner includes permitting the implant to dissolve over time.

28. The method of claim 16, wherein placing the implant includes placing the first end of the implant in flow communication with a left ventricle.

29. The method of claim 16, wherein placing the implant includes placing the first end of the implant in flow communication with a coronary artery.

30. The method of claim 16, wherein placing the implant includes placing the second end of the implant within the heart wall.

31. The method of claim 16, wherein the agent is a biologically active agent.

32. A method of treating a heart, the method comprising:

providing an implant having a first end and a second end;

placing th implant in a heart wall such that the first end of the implant is in flow communication with a heart chamber and the second end of the implant is in flow communication with a blood vessel;

delivering an angiogenesis factor to the heart wall proximate the implant, and

controlling the rate of the delivery of the angiogenesis factor,

wherein the implant is porous and controlling the rate of the delivery includes controlling a porosity of the implant.

33. The method of claim 32, further comprising delivering at least one additional agent to the heart wall proximate the implant.

34. The method of claim 33, wherein delivering the angiogenesis factor and the at least one additional agent includes delivering the angiogenesis factor and the at least one additional agent via an implant having the angiogenesis factor and the at least one additional agent applied thereto.

35. The method of claim 34, further comprising controlling the rate of delivery of each of the angiogenesis factor and the at least one additional agent.

36. The method of claim 32, wherein delivering the angiogenesis factor includes delivering the angiogenesis factor via the implant.

37. The method of claim 36, wherein the implant is configured to car the angiogenesis factor.

38. The method of claim 32, wherein the implant includes a stent.

39. The method of claim 32, wherein the implant includes a plug.

40. The method of claim 32, wherein placing the implant includes placing the first end of the implant in flow communication with a left ventricle.

41. The method of claim 32, wherein placing the implant includes placing the second end of the implant in flow communication with a coronary artery.

42. The method of claim 32, wherein delivering the angiogenesis factor includes permitting the implant to degrade over time.

43. The method of claim 32, wherein delivering the angiogenesis factor includes permitting the implant to be absorbed by the heart wall over time.

44. The method of claim 32, wherein delivering the angiogenesis factor includes permitting the implant to dissolve over time.

45. A method of treating a heart, the method comprising:

providing an implant having a first end and a second end;

placing the implant in a heart wall such that the first end of the implant is in flow communication with a heart chamber and the second end of the implant is in flow communication with a blood vessel;

delivering an agent to the heart wall proximate the implant; and

controlling the rate of the delivery of the agent,

wherein the implant is coated with a layer including the agent,

wherein the implant is porous and controlling the rate of the delivery includes controlling a porosity of the implant.

46. The method of claim 45, further comprising delivering at least one additional agent to the heart wall proximate the implant.

47. The method of claim 46, wherein delivering the agents includes delivering the agents via an implant having multiple agents applied thereto.

48. The method of claim 47, further comprising controlling the rate of delivery of each of the agents.

49. The method of claim 45, wherein the implant includes a stent.

50. The method of claim 45, wherein the implant includes a plug.

51. The method of claim 45, wherein the agent is chosen from angiogenesis factors, nucleic acid instructions for angiogenesis factors, growth factors, genes, drugs, and pharmaceutical compounds.

52. The method of claim 45, wherein the layer is made of a polymeric material.

53. The method of claim 45, wherein placing the implant includes placing the first end of the implant in flow communication with a left ventricle.

54. The method of claim 45, wherein placing the implant includes placing the second end of the implant in flow communication with a coronary artery.

55. The method of claim 45, wherein delivering the agent includes permitting the implant to degrade over time.

56. The method of claim 45, wherein delivering the agent includes permitting the implant to be absorbed by the heart wall over time.

57. The method of claim 45, wherein delivering the agent includes permitting the implant to dissolve over time.

58. The method of claim 45, wherein the agent is a biologically active agent.